Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype

摘要

Background: Mepolizumab is approved for patients with severe asthma with an eosinophilic phenotype aged 12 or more (United States) or 6 or more (European Union) years, but its long-term use in children aged 6 to 11 years has not yet been assessed.